This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-11 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
2, 8, 8, 18, 18, 32, 32, ... The overlaps get quite close at the point where the d orbitals enter the picture, and the order can shift slightly with atomic number and atomic charge. Starting from the simplest atom, this lets us build up the periodic table one at a time in order of atomic number, by considering the cases of single atoms. In hydrogen, there is only one electron, which must go in the lowest-energy orbital 1s. This electron configuration is written 1s1, where the superscript indicates the number of electrons in the subshell. Helium adds a second electron, which also goes into 1s, completely filling the first shell and giving the configuration 1s2. Starting from the third element, lithium, the first shell is full, so its third electron occupies a 2s orbital, giving a 1s2 2s1 configuration. The 2s electron is lithium's only valence electron, as the 1s subshell is now too tightly bound to the nucleus to participate in chemical bonding to other atoms: such a shell is called a "core shell". The 1s subshell is a core shell for all elements from lithium onward. The 2s subshell is completed by the next element beryllium (1s2 2s2). The following elements then proceed to fill the 2p subshell. Boron (1s2 2s2 2p1) puts its new electron in a 2p orbital; carbon (1s2 2s2 2p2) fills a second 2p orbital; and with nitrogen (1s2 2s2 2p3) all three 2p orbitals become singly occupied. This is consistent with Hund's rule, which states that atoms usually prefer to singly occupy each orbital of the same type before filling them with the second electron.
==== Libya ==== The mummified remains of an infant were discovered during an expedition by archaeologist Fabrizio Mori to Libya during the winter of 1958–1959 in the natural cave structure of Uan Muhuggiag. After curious deposits and cave paintings were discovered on the surfaces of the cave, expedition leaders decided to excavate. Uncovered alongside fragmented animal bone tools was the mummified body of an infant, wrapped in animal skin and wearing a necklace made of ostrich egg shell beads. Professor Tongiorgi of the University of Pisa radiocarbon-dated the infant to between 5,000 and 8,000 years old. A long incision located on the right abdominal wall, and the absence of internal organs, indicated that the body had been eviscerated post-mortem, possibly in an effort to preserve the remains. A bundle of herbs found within the body cavity also supported this conclusion. Further research revealed that the child had been around 30 months old at the time of death, though sex could not be determined due to poor preservation of the sex organs.
=== Diabetes Mellitus === Increased levels of proinsulin in the circulatory system relative to mature insulin concentrations can indicate impending insulin resistance and the development of type 2 diabetes. Additional problems with proinsulin that can lead to diabetes include mutations in the number of cysteines present, which could affect correct folding. If the mutation causes only a mild change it could simply stress the endoplasmic reticulum’s ability to properly fold the protein. This stress, after a while, would lead to a decrease in the number of β-cells producing mature insulin, and would then lead to diabetes mellitus.
Progesterone and some of its metabolites, such as 5β-dihydroprogesterone, are agonists of the pregnane X receptor (PXR), albeit weakly so (EC50 >10 μM). In accordance, progesterone induces several hepatic cytochrome P450 enzymes, such as CYP3A4, especially during pregnancy when concentrations are much higher than usual. Perimenopausal women have been found to have greater CYP3A4 activity relative to men and postmenopausal women, and it has been inferred that this may be due to the higher progesterone levels present in perimenopausal women. Progesterone modulates the activity of CatSper (cation channels of sperm) voltage-gated Ca2+ channels. Since eggs release progesterone, sperm may use progesterone as a homing signal to swim toward eggs (chemotaxis). As a result, it has been suggested that substances that block the progesterone binding site on CatSper channels could potentially be used in male contraception.
Sources: en.wikipedia.org
== Overview == In electronics, one of the earliest devices using the principle are ultrasonic distance-measuring devices, which emit an ultrasonic pulse and are able to measure the distance to a solid object based on the time taken for the wave to bounce back to the emitter. The ToF method is also used to estimate the electron mobility. Originally, it was designed for measurement of low-conductive thin films, later adjusted for common semiconductors. This experimental technique is used for metal-dielectric-metal structures as well as organic field-effect transistors. The excess charges are generated by application of the laser or voltage pulse.
==== Elimination ==== Tizanidine is eliminated 60% in urine and 20% in feces. Its elimination half-life is approximately 2.5 hours. The inactive metabolites of tizanidine have half-lives of 20 to 40 hours.
In May 2000, the GSI successfully repeated the experiment to synthesize a further atom of copernicium-277. This reaction was repeated at RIKEN using the Search for a Super-Heavy Element Using a Gas-Filled Recoil Separator set-up in 2004 and 2013 to synthesize three further atoms and confirm the decay data reported by the GSI team. This reaction had also previously been tried in 1971 at the Joint Institute for Nuclear Research in Dubna, Russia to aim for 276Cn (produced in the 2n channel), but without success. Work had also been done there from 1998 to synthesize the heavier isotope 283Cn in the hot fusion reaction 238U(48Ca,3n)283Cn; most observed atoms of 283Cn decayed by spontaneous fission, although an alpha decay branch to 279Ds was detected. While initial experiments aimed to assign the produced nuclide with its observed long half-life of 3 minutes based on its chemical behaviour, this was found to be not mercury-like as would have been expected (copernicium being under mercury in the periodic table), and indeed now it appears that the long-lived activity might not have been from 283Cn at all, but its electron capture daughter 283Rg instead, with a shorter 4-second half-life associated with 283Cn.
== Bibliography == Ballard, J. G. (1964). The Terminal Beach. Carroll and Graf. The Terminal Beach at Google Books; reprint (1997): ISBN 0-88184-370-9. Bureau of Yards and Docks (1947). Building the Navy's Bases in World War II: History of the Bureau of Yards and Docks and the Civil Engineer Corps, 1940–1946. U.S. Department of the Navy; U.S. Government Printing Office. Hezel, Francis X. (1994) [1983]. The First Taint of Civilization: A History of the Caroline and Marshall Islands in Pre-colonial Days, 1521–1885. University of Hawaii Press. ISBN 978-0-8248-1643-8. Roberts, Michael D. (2000). Dictionary of American Naval Aviation Squadrons. Vol. 2: The History of VP, VPB, VP(H) and VP(AM) Squadrons. Washington, D.C.: Naval Historical Center, Department of the Navy. Retrieved 2015-01-22. Attribution This article incorporates public domain material from the Air Force Historical Research Agency
Hematopathology or hemopathology (both also spelled haem-, see spelling differences) is the study of diseases and disorders affecting and found in blood cells, their production, and any organs and tissues involved in hematopoiesis, such as bone marrow, the spleen, and the thymus. Diagnoses and treatment of diseases such as leukemia and lymphoma often deal with hematopathology; techniques and technologies include flow cytometry studies and immunohistochemistry. In the United States, hematopathology is a board-certified subspecialty by the American Board of Pathology. Board-eligible or board-certified hematopathologists are usually pathology residents (anatomic, clinical, or combined) who have completed hematopathology fellowship training after their pathology residency. The hematopathology fellowship lasts either one or two years. A physician who practices hematopathology is called a hematopathologist.
Sources: en.wikipedia.org
123I is produced by proton irradiation of 124Xe. The caesium isotope produced is unstable and decays to 123I. The isotope is usually supplied as the iodide and hypoiodate in dilute sodium hydroxide solution, at high isotopic purity. 123I has also been produced at Oak Ridge National Laboratories by proton bombardment of 123Te. 123I decays by electron capture with a half-life of 13.22 hours. The emitted 159 keV gamma ray is used in single-photon emission computed tomography (SPECT). A 127 keV gamma ray is also emitted. 125I is frequently used in radioimmunoassays because of its relatively long half-life (59 days) and ability to be detected with high sensitivity by gamma counters. 129I is present in the environment as a result of the testing of nuclear weapons in the atmosphere. It was also produced in the Chernobyl and Fukushima disasters. 129I decays with a half-life of 15.7 million years, with low-energy beta and gamma emissions. It is not used as a tracer, though its presence in living organisms, including human beings, can be characterized by measurement of the gamma rays.
== History == Relugolix was first described in 2004. It superseded sufugolix (developmental code name TAK-013), which was developed by the same researchers. Relugolix was approved for the treatment of uterine fibroids in Japan in January 2019. It was the second orally active GnRH antagonist to be introduced for medical use, following elagolix (brand name Orilissa) in July 2018. Relugolix was approved for the treatment of prostate cancer in the United States on 18 December 2020. The FDA approved relugolix based on evidence from a clinical trial (NCT03085095) of 930 participants 48 to 97 years old with advanced prostate cancer. The trial was conducted at 155 sites in the United States, Canada, and countries in South America, Europe and the Asia Pacific region. All participants in the trial had advanced prostate cancer. Participants were randomly assigned to receive either one relugolix tablet daily (on the first day they received three tables) or an active control (leuprolide acetate) which was given as an injection under the skin every three months. The participants and healthcare providers were aware of which treatment was being given. The treatment lasted for 48 weeks. The efficacy of relugolix was assessed by the percentage of participants who achieved and maintained low testosterone level equal to castration.
=== Radioiodine === In iodine-131 (radioiodine) radioisotope therapy, which was first pioneered by Dr. Saul Hertz, radioactive iodine-131 is given orally (either by pill or liquid) on a one-time basis, to severely restrict, or altogether destroy the function of a hyperactive thyroid gland. This isotope of radioactive iodine used for ablative treatment is more potent than diagnostic radioiodine (usually iodine-123 or a very low amount of iodine-131), which has a biological half-life of 8–13 hours. Iodine-131, which also emits beta particles that are far more damaging to tissues at short range, has a half-life of approximately 8 days. People not responding sufficiently to the first dose are sometimes given an additional radioiodine treatment at a larger dose. Iodine-131 in this treatment is picked up by the active cells in the thyroid and destroys them, rendering the thyroid gland mostly or completely inactive. Since iodine is picked up more readily (though not exclusively) by thyroid cells, and (more importantly) is picked up even more readily by overactive thyroid cells, the destruction is local, and there are no widespread side effects with this therapy. Radioiodine ablation has been used for over 50 years, and the only major reasons for not using it are pregnancy and breastfeeding (breast tissue also picks up and concentrates iodine). Once the thyroid function is reduced, replacement hormone therapy (levothyroxine) taken each day orally replaces the thyroid hormone that is normally produced by the body.
Basic stocks are usually named for the primary meat type. A distinction is usually made between fond blanc, or white stock, made by using raw bones and mirepoix, and fond brun, or brown stock, which gets its color by roasting the bones and mirepoix before boiling; the bones may also be coated in tomato paste before roasting. Chicken is most commonly used for fond blanc, while beef or veal are most commonly used in fond brun. Other regional varieties include:
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.